公司概况
Oncimmune Holdings plc develops and commercializes products to diagnose cancer in the United Kingdom, North America, Europe, and internationally. It offers EarlyCDT-Lung, a blood test for early detection of lung cancer. The company also develops EarlyCDT-Liver, a blood test for the early detection of hepatocellular carcinoma in high-risk patients with liver lesions of all sizes; SeroTag, a platform that is used to discover and validate biomarkers and develop precision diagnostic tools from minimally-invasive liquid biopsies; and NavigAID for autoimmune diseases. Oncimmune Holdings plc was incorporated in 2015 and is based in Nottingham, the United Kingdom.